These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1085788)

  • 21. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin.
    Smith CR; Lipsky JJ; Laskin OL; Hellmann DB; Mellits ED; Longstreth J; Lietman PS
    N Engl J Med; 1980 May; 302(20):1106-9. PubMed ID: 6988713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Ototoxicity of tobramycin and other aminoglycosides (comparative studies)].
    Federspil P
    Nouv Presse Med; 1978 Nov; 7(42):3846-8. PubMed ID: 714690
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug-induced tinnitus and other hearing disorders.
    Seligmann H; Podoshin L; Ben-David J; Fradis M; Goldsher M
    Drug Saf; 1996 Mar; 14(3):198-212. PubMed ID: 8934581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The importance of audiometric monitoring in patients with multidrug-resistant tuberculosis.
    Vasconcelos KA; Frota SMMC; Ruffino-Netto A; Kritski AL
    Rev Soc Bras Med Trop; 2017; 50(5):646-651. PubMed ID: 29160511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous injection of gentamicin and tobramycin without impairment of hearing.
    Dobbs SM; Mawer GE
    J Infect Dis; 1976 Aug; 134 Suppl():S114-7. PubMed ID: 972268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A study of the cochleo-vestibular tolerance of tobramycin in man. Preliminary study].
    Brogard JM; Conraux C; Collard M; Jahn H; Lavillaureix J
    Nouv Presse Med; 1974 Apr; 3(0):75-9. PubMed ID: 4600182
    [No Abstract]   [Full Text] [Related]  

  • 27. [Evaluation of the ototoxicity of aminoglycosides. Comparative study of dibekacin, gentamicin and tobramycin].
    Aran JM
    Nouv Presse Med; 1982 Nov; 11(46):3426-31. PubMed ID: 7155851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aminoglycoside ototoxicity. An update, with implications for all drug therapies.
    Johnson JT; Kamerer DB
    Postgrad Med; 1985 Apr; 77(5):131-4, 138. PubMed ID: 3872449
    [No Abstract]   [Full Text] [Related]  

  • 29. [Cochlear-vestibular ototoxicity by gentamicin. Report of a case and literature review].
    Pino Rivero V; Marcos García M; Keituqwa Yáñez T; González Palomino A; Trinidad Ruiz G; Pardo Romero G; Blasco Huelva A
    An Otorrinolaringol Ibero Am; 2004; 31(6):531-7. PubMed ID: 15663084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recognizing and avoiding ototoxicity.
    Aagaard GN
    Postgrad Med; 1972 Oct; 52(4):141-5. PubMed ID: 4538456
    [No Abstract]   [Full Text] [Related]  

  • 31. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
    Mulheran M; Hyman-Taylor P; Tan KH; Lewis S; Stableforth D; Knox A; Smyth A
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2293-9. PubMed ID: 16801404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Audiologic threshold monitoring of patients receiving ototoxic drugs. Preliminary report.
    Meyerhoff WL; Maale GE; Yellin W; Roland PS
    Ann Otol Rhinol Laryngol; 1989 Dec; 98(12 Pt 1):950-4. PubMed ID: 2589763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Retrospective study on a possible ototoxicity of tobramycin in the newborn infant].
    Giaccai F; Bigozzi M; Salimbeni C; Periti P
    Clin Ter; 1975 Dec; 75(5):479-89. PubMed ID: 1218464
    [No Abstract]   [Full Text] [Related]  

  • 35. Vestibular ototoxicity in children: a retrospective study of 52 cases.
    Camarda V; Moreno AM; Boschi V; Di Carlo A; Spaziani G; Saponara M
    Int J Pediatr Otorhinolaryngol; 1981 Sep; 3(3):195-8. PubMed ID: 6976334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.
    Dong M; Rodriguez AV; Blankenship CA; McPhail G; Vinks AA; Hunter LL
    J Antimicrob Chemother; 2021 Oct; 76(11):2923-2931. PubMed ID: 34379758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency.
    Edson RS; Brey RH; McDonald TJ; Terrell CL; McCarthy JT; Thibert JM
    Mayo Clin Proc; 2004 Sep; 79(9):1185-91. PubMed ID: 15357042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical nephrotoxicity of tobramycin and gentamicin. A prospective study.
    Kumin GD
    JAMA; 1980 Oct; 244(16):1808-10. PubMed ID: 7420681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of netilmicin and tobramycin therapy in patients with renal impairment.
    Gorse GJ; Bernstein JM; Cronin RE; Etzell PS
    Scand J Infect Dis; 1992; 24(4):503-14. PubMed ID: 1411317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Audiologic monitoring for potential ototoxicity in a phase I clinical trial of a new glycopeptide antibiotic.
    Campbell KC; Kelly E; Targovnik N; Hughes L; Van Saders C; Gottlieb AB; Dorr MB; Leighton A
    J Am Acad Audiol; 2003 Apr; 14(3):157-68; quiz 170-1. PubMed ID: 12859140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.